Dr Melinda Ashcroft is a Research Fellow on Infectious Disease Epidemiology (Climate Change) in the Faculty of Medicine at The University of Queensland (UQ). Her current research focus is on Nontuberculous mycobacteria (NTM) and how NTM infections are associated with climate change and major weather events. Previously Melinda has worked at Monash University as a Research Fellow on the Sero-epidemiology of Klebsiella spp., at the University of Melbourne as a Postdoctoral Research Fellow on the Genomic Epidemiology of Neisseria gonorrhoeae and as a Research Associate at UQ on the genomics and epigenomics of extraintestinal pathogenic Escherichia coli. Melinda was awarded a Bachelor of Applied Science (Biotechnology/Biochemistry) in 2004 from Queensland University of Technology and a Master of Biotechnology in 2013 from UQ. She then switched fields to Microbial Genomics and was awarded a PhD from UQ in 2019 for her thesis: Evolution and function of mobile genetic elements and DNA methyltransferases in extraintestinal pathogenic Escherichia coli.
Scott Beatson is an Associate Professor and NHMRC Career Development Fellow at The University of Queensland (UQ). He specializes in bacterial pathogenomics: using whole-genome sequencing to investigate transmission, pathogenesis and antibiotic resistance in bacteria. Recent work from his group includes genomic analyses of pandrug resistant enterobacteriaceae and the multidrug resistant Escherichia coli ST131 pandemic clone. He was awarded a PhD from UQ for his work in bacterial pathogenesis in 2002 and developed his career in bacterial genomics in the United Kingdom with the support of fellowships from the Royal Commission for the Exhibition of 1851 (University of Oxford) and the UK Medical Research Council (University of Birmingham). Since returning to Australia he has held fellowships from both the NHMRC and ARC and has led a successful research group in the School of Chemistry and Molecular Biosciences at UQ since 2008. He is also a member of the Australian Infectious Diseases Research Centre and the Australian Centre for Ecogenomics. In 2016 he received the Frank Fenner Award from the Australian Society for Microbiology in recognition of his contribution to microbiology research in Australia.
Dr. Bialasiewicz worked at the Royal Children's Hospital and the Children's Health Queensland HHS for over 18 years conducting translational research and clinical support centering on infectious disease (primarily viral and bacterial) molecular diagnostics, general microbiology and molecular epidemiology. In 2019, he became a group leader at The University of Queensland's Australian Centre for Ecogenomics, expanding on a growing interest in the microbial ecology of the human body, it's role in health and disease, and ways to manipulated to achieve desirable outcomes. One Health microbial ecology, where human health is interconnected with the health of animals (both livestock and wildlife), and the broader environment is also an area of active interest. His background in virology has influenced the work he does, meaning a key focus of his microbial ecology works centres around the interactions between all types of microorgansims (bacteria, archaea, viruses, fungi, and micro-eukaryotes).
Ongoing work includes:
- Leveraging of emerging technologies to explore the hidden microbial diversity and their interactions in the human body.
- Using the technology to develop microbial (e.g. phage)-based treatments or preventatives to complex diseases (e.g. Otitis Media, Chronic Rhinosinusitis, GvHD).
- Understanding the genetics of antibiotic resistance spread.
Professor Antje Blumenthal combines her expertise in immunology and microbiology to lead research on molecular mechanisms that control immune responses to infection, alongside more recently developed research on new antimicrobials. The overall goal of her research is to improve our ability to treat severe bacterial infections as part of the global efforts to overcome the threat posed by antibiotic-resistant bacteria. Prof Blumenthal graduated with a major in Microbiology from the Christian-Albrechts-University in Kiel, Germany, pursued PhD research in Immunology at the Leibniz Research Center for Medicine and Biosciences Borstel, Germany, and undertook postdoctoral training at Weill Cornell Medical College, New York, USA. She joined The University of Queensland Diamantina Institute in 2010 where she leads the Infection & Inflammation Group, fostering cross-disciplinary collaborations with immunologists, microbiologists, chemists, clinical research teams and industry partners. Her research is enabled by major funding from international and national agencies, and has been recognised internationally and nationally by prestigious awards, speaking invitations at eminent conferences and institutions, invitations to peer-review for esteemed journals and funding agencies. Prof Blumenthal is an enthusiastic undergraduate teacher and research student advisor. She is proactive in advancing the careers of junior scientists, leads the development and implementation of initiatives that promote equity, diversity and inclusion in science, and a positive workplace culture. Through leadership roles within the University and professional societies as well as editorial roles for international journals, Prof Blumenthal actively contributes to the scientific community.
Dr Andrew Brooks is the Group Leader of the Cytokine Receptor Signalling Group at the University of Queensland Diamantina Institute (UQ DI) within the Translational Research Institute. Andrew completed his Honours research on Flaviviruses in 1996 at the Department of Microbiology and Immunology at James Cook University and then moved to the Department of Biochemistry to study Dengue Virus where he completed his PhD in 2002. He then moved to St Jude Children’s Research Hospital in Memphis, TN, USA where he researched the role of Epstein-Barr Virus in B-cell lymphomagenesis. He then joined the research group headed by Prof Michael Waters at the Institute for Molecular Bioscience, UQ in 2006 and subsequently began his independent research group at UQ DI in 2014. Andrew’s research interests are in cytokine receptors, cell signalling, oncogenesis, and immunology. His current research focus is on the molecular mechanisms of class I cytokine receptor activation including the growth hormone receptor (GHR), thrombopoietin receptor (TpoR/MPL), IL-7 receptor, and IL-6 receptor (IL-6R). In addition, he is investigating the regulation of inflammation by HLA-G. His research has led to publications in journals including Science, Blood, Hepatology, Oncogene, Nature Cell Biology, and PNAS. He has been the secured of over $12 million in research and commercialisation funding from sources including NHMRC, ARC, Innovation Connections, and Merck. He has a number of national and international collaborations, a scientific founder of a start-up company, and is an Editorial Board member for the Journal Cancers and Human Cell. He was previously a committee member of Australian Early-Mid Career Researchers Forum (AEMCRF) launched by the Australian Academy of Science.
Dr Fernanda Cardoso is a Brazil-born Australian researcher interested in venom peptide-based biodiscovery and therapeutics development. Cardoso was awarded an MSc in Molecular Pharmacology and a PhD with an emphasis in Biochemistry and Immunology and is part of the Institute for Molecular Bioscience, where she develops novel therapies for complex neurological diseases. Cardoso has interdisciplinary training in the fields of neuropharmacology, medicinal chemistry and chemical biology and a strong background in drug discovery, which provides the skills to identify naturally occurring or synthetic bioactive molecules and to study their effects in human physiology with applications in neurologic disorders such as chronic pain, irritable bowel syndrome (IBS), and motor neuron disease (MND). Please see Dr Cardoso’s Grants and Publications list for more details.
Before joining the University of Queensland, Dr Cardoso was part of the Queensland Institute for Medical Research, holding a prestigious CAPES Postdoctoral Fellowship. During this period, Cardoso developed unique high-throughput screen platforms for discovering protein and peptide targets of novel therapies to combat infectious diseases and novel helminth-derived bioactives with anti-inflammatory properties. Please see Dr Cardoso’s Publications list for more details.
Dr Cardoso is currently part of the Centre for Drug Discovery and manages several industry and academic projects studying ion channel modulators derived from natural repertoires, particularly venoms, and developing novel, effective drugs to treat neurological disorders.
Australian Institute for Bioengineering and Nanotechnology
Professorial Research Fellow
School of Chemistry and Molecular Biosciences
Faculty of Science
Availability:
Available for supervision
Keith is Molecular Virologist and group leader with a dual appointment within the Australian Bioengineering and Nanotechnology Institute and the School of Chemistry and Molecular Biosciences. His research is focused on vaccine development and the understanding of medically and environmentally significant viruses. Keith is one of the inventors of a UQ’s molecular clamp platform and is the co-leader of a program to produce a vaccine for COVID-19 at UQ. Keith has played a leading role in designing and implementing an epidemic response vaccine pipeline which enabled the progression of UQ’s COVID-19 vaccine candidate from sequence information to clinical trial dosing within 6 months.
Keith completed his PhD at the University of Queensland in 2007 on the structure and function of flavivirus NS3 protease. Subsequently, he spent three years (2007-2010) as a post-doctoral researcher at one of Spain’s most respected research institutes, Instituto Salud Carlos III, where I conducted research on the fusion protein of Respiratory Syncytial viurs as a target for conformationally specific neutralizing antibodies. Keith returned to UQ in 2011 and his research has focused on understanding of many medically and environmentally important viruses and bacteria, particularly focussing on Influenza, Respiratory Syncytial virus (RSV), SARS-CoV-2, Koala Retrovirus and Streptococcus pneumoniae.
Queensland Alliance for Agriculture and Food Innovation
Associate Professor in Env Science
School of the Environment
Faculty of Science
Availability:
Available for supervision
Paul Dennis leads an exciting research group that applies cutting-edge technologies to understand the roles of microorganisms and their responses to environmental change.
He is also a passionate educator and public speaker who advocates for the importance of biological diversity and evidence-based environmental awareness. He has talked about his research on ABC Radio and a range of other media outlets.
His teaching covers aspects of ecology, microbiology, plant and soil science, and climatology. He considers these topics to be of fundamental importance for the development of more sustainable societies and takes pride in helping others to obtain the knowledge and skills they need to build a better future.
Paul's research has taken him to Antarctica, the Amazon Rainforest, high mountains and oceans. The approaches used in his lab draw on a wide range of expertise in molecular biology, ecology, statistics, computer science, advanced imaging and soil science. He applies these skills to a wide-range of topics and systems including plant-microbe interactions, Antarctic marine and terrestrial ecology, biogeography, pollution and human health.
Professor Denise Doolan is Director of Research at the Institute for Molecular Bioscience. She joined IMB in 2022 and was previously Deputy Director of the Australian Institute of Tropical Health and Medicine, and Director of the JCU Centre for Molecular Therapeutics, at James Cook University.
She is a molecular immunologist, working on the development of vaccines, diagnostics and host-directed therapeutics for infectious and chronic diseases that impact global public health, with a particular focus on malaria. Her cross-disciplinary research program spans host-pathogen immunity, antigen discovery, vaccine engineering, and biomarker discovery. A particular interest is the application of state-of-the-art genome-based technologies and human models of disease system to identify novel targets for intervention against disease or that predict risk of disease.
She is a recognized world expert in malaria immunology, vaccinology, and omic-based approaches for therapeutic and diagnostic development. She has been honoured as a Fellow of the International Society for Vaccines (2017) and a Fellow of the Australian Society of Parasitology (2019) in recognition of her leadership and contribution to health and medical science in Australia and internationally.
Professor Doolan serves on a number of Executive Boards and Advisory Boards. Most recently, she has been elected as President of the International Society for Vaccines (2021-2023), and has been appointed to the Federal Government’s Australian Medical Research Advisory Board (AMRAB; 2021-2026) to provide specialist insights into Australia’s medical research and innovation priorities.
Dr Christian Gray joined the Academy of Medical Education as a Senior Lecturer in 2019 and is a course coordinator and module lead. Prior to this, Dr Gray was a Lecturer in Infection and Immunity and was Immunology discipline lead at Peninsula Medical School at the University of Plymouth, Devon, UK.
Dr Gray has previously undertaken Postdoctoral research in a variety of areas in immunological research including therapies for rheumatoid arthritis, pneumococcal vaccines, mastitis resistance in dairy cattle, and vaccines for R. microplus. He obtained his PhD from the University of Newcastle, Australia in 2002. He was the first to identify a link between activation of regulatory T cells and the suppression of the immune system in patients with melanoma.
Within his current role he have transferred his skills from biomedical research into pedagogy of teaching and learning. He is actively developing a research portfolio within medical research focusing on the support of student learning.
Faculty of Engineering, Architecture and Information Technology
Research Fellow
Australian Institute for Bioengineering and Nanotechnology
Availability:
Available for supervision
Dr. Wenyi Gu’s early education was conducted in China which include his undergraduate and master’s degrees in veterinary medicine. In 1996, he migrated to Australia and pursued his PhD study in biochemistry & molecular biology at the Australian National University (ANU). After a short period of work at John Curtin Medical School ANU as a junior scientist, he moved to Brisbane in 2001 for his post-doc at the University of Queensland and currently a post-doctoral research fellow at AIBN. He held a Peter Doherty Fellowship (2006-2009) and was further supported by NHMRC to spend 7 months at Harvard University as a visiting fellow in 2008. Since his post-doctoral research he has been working in the area of using RNAi to treat viral diseases and cancers. He also has a strong background in immunology and vaccine development.
I lead a research program with extensive expertise in immunology, particularly in natural killer (NK) cells, focused on developing innovative approaches for treating hard-to-cure diseases like metastatic cancers. Our mission is to improve patient outcomes and extend lives. My research group is based at the Translational Research Institute (TRI).
My dedication to my field has been recognized through numerous peer-reviwed grants as sole-CI or CIA/Principal Investigator, including a NHMRC ECF Peter Doherty Fellowship, an NHMRC Project Grant, an US DoD, a MRFF EMCR among others. Since 2009, I've amassed an impressive portfolio of 96 publications in renowned journals like Blood, Cell Death Dis, JEM, PNAS, Nat Comms, and Nat Immunol with an H-index = 40. My body of work and contributions have been acknowledged with awards such as the 2019 Researcher of the Year by CCA, 2020 QLD Young Tall Poppy Science, 2020 UQ Frazer Institute's Rising Star, 2022 Frazer Institute's Mentor of the Year, 2023 Translational Research Institute - Connecting with the Clinic among others. Recognized as an international leader in my field, I've been instrumental in identifying novel regulators of our immune functions, and developing NK cell-based immunotherapies.
At present, I am a Group Leader / Principal Research Fellow & Associate Professor with the University of Queensland's Frazer Institute. Here, I lead a high-performing research team with a keen focus on developing and innovating immunotherapy approaches for a spectrum of diseases.
Associate Professor Emma Hamilton-Williams’ career focuses on understanding how immune tolerance is disrupted leading to the development of the autoimmune disease type 1 diabetes. She received her PhD from the Australian National University in 2001, followed by postdoctoral training in Germany and the Scripps Research Institute in the USA.
In 2012, she started a laboratory at the Frazer Institute, University of Queensland where she investigates the gut microbiota as a potential trigger or therapy target for type 1 diabetes, as well as developing an immunotherapy for type 1 diabetes. The overall aim of her research is to find new ways to prevent or treat the underlying immune dysfunction causing autoimmunity.
She is Chief Scientific Officer for an Australia-wide pregnancy-birth cohort study of children at increased risk of type 1 diabetes, which aims to uncover the environmental drivers of this disease. Her laboratory uses big-data approaches including proteomics, metabolomics and metagenomics to understand the function of the gut microbiota linked to disease.
She recently conducted a clinical trial of a microbiome-targeting biotherapy aimed at restoring a healthy microbiome and immune tolerance, with an ultimate aim of preventing type 1 diabetes.
Alexander Khromykh has PhD degree in Molecular Virology. He worked as Postdoctoral Fellow at the University of Ottawa in Canada. He then joined Sir Albert Sakzewski Virus Research Centre in Brisbane and became a laboratory Head in 2001. He moved his laboratory to St Luica campus in 2005 to take an appointment with the School of Chemistry and Molecular Biosciences (SCMB). He was the founding Director of the SCMB’s Centre for Infectious Disease Research and is currently the Deputy Director of the Australian Infectious Diseases Research Centre. He is also the Director of Centre of Excellence and a member of COVID-19 and Zika virus Task Forces in the Global Virus Network.
Dr. Larisa Labzin studies how our innate immune system detects viral infections and how it decodes different signals to mount an appropriate immune response. Dr. Labzin's interest in innate immunity started during her honours training with Prof. Matt Sweet at the IMB, looking at how inflammatory signalling is regulated in macrophages. After gaining more experience while working as a research assistant for Prof. Sweet, she moved to Germany to the University of Bonn for her PhD. At the Univeristy of Bonn, Dr. Labzin investigated the anti-inflammatory effects of High-Density Lipoprotein with Prof. Eicke Latz. Here she discovered novel regulatory pathways that control inflammation. Dr. Labzin then moved to Cambridge, UK as an EMBO postdoctoral fellow to work with Dr. Leo James at the Medical Research Council Laboratory for Molecular Biology. In Dr. James' lab Dr. Labzin focused on how viruses are sensed by the innate immune system to trigger inflammation. In particular, Dr Labzin investigated how antibodies change the way viruses trigger inflammation. While in Cambridge, Dr. Labzin was awarded an NHMRC CJ Martin Fellowship to return to Australia. Larisa returned to the IMB in September 2019 to work with Prof. Kate Schroder. Dr. Labzin is an IMB Fellow and leads an independent research team studying inflammation in response to influenza and SARS-CoV-2.
